Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

BACKGROUND: Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%. METHODS: This updated figure was applied to a previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Strutton, David R, Farkouh, Raymond A, Rubin, Jaime L, McGarry, Lisa J, Loiacono, Paul M, Klugman, Keith P, Pelton, Steven I, Gilmore, Kristen E, Weinstein, Milton C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426485/
https://www.ncbi.nlm.nih.gov/pubmed/22863074
http://dx.doi.org/10.1186/1471-2334-12-175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426485/
https://www.ncbi.nlm.nih.gov/pubmed/22863074
http://dx.doi.org/10.1186/1471-2334-12-175

Ejemplares similares